blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3142674

EP3142674 - METHODS AND COMPOSITIONS FOR TREATMENT OF MACROPHAGE-RELATED DISORDERS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  07.12.2018
Database last updated on 25.09.2024
FormerRequest for examination was made
Status updated on  17.02.2017
FormerThe international publication has been made
Status updated on  30.11.2016
Most recent event   Tooltip07.12.2018Application deemed to be withdrawnpublished on 09.01.2019  [2019/02]
Applicant(s)For all designated states
Neuraltus Pharmaceuticals, Inc.
1001 Bayhill Drive
Suite 300
San Bruno, California 94066 / US
For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
[2017/12]
Inventor(s)01 / MCGRATH, Michael S.
1452 Benito Avenue
Burlingame, California 94010 / US
02 / BLOCK, Gilbert
2479 E. Bayshore Road
Suite 220
Palo Alto, California 94303 / US
 [2017/12]
Representative(s)Avidity IP
Broers Building
Hauser Forum
21 JJ Thomson Avenue
Cambridge CB3 0FA / GB
[N/P]
Former [2017/12]Cummings, Ross Martin, et al
Avidity IP
Broers Building
Hauser Forum
21 J.J. Thomson Avenue
Cambridge CB3 0FA / GB
Application number, filing date15792274.115.05.2015
[2017/12]
WO2015US31145
Priority number, dateUS201461994736P16.05.2014         Original published format: US 201461994736 P
US201462051849P17.09.2014         Original published format: US 201462051849 P
[2017/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015175974
Date:19.11.2015
Language:EN
[2015/46]
Type: A1 Application with search report 
No.:EP3142674
Date:22.03.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 19.11.2015 takes the place of the publication of the European patent application.
[2017/12]
Search report(s)International search report - published on:US19.11.2015
(Supplementary) European search report - dispatched on:EP20.12.2017
ClassificationIPC:A61K33/20, C01B11/10, A61P25/28, A61K33/00, G01N33/68
[2018/03]
CPC:
A61K33/20 (EP,US); A61K33/00 (EP,US); A61P21/02 (EP);
A61P25/16 (EP); A61P25/28 (EP); C01B11/10 (EP,US);
G01N33/6896 (EP,US); G01N2333/70535 (EP,US); G01N2333/70539 (EP,US);
G01N2800/2821 (EP,US); G01N2800/2835 (EP,US); G01N2800/52 (US);
G01N2800/7095 (EP,US) (-)
Former IPC [2017/12]A61K33/20, C01B11/10, A61P25/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/12]
Extension statesBA30.11.2016
ME30.11.2016
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT MAKROPHAGEN[2017/12]
English:METHODS AND COMPOSITIONS FOR TREATMENT OF MACROPHAGE-RELATED DISORDERS[2017/12]
French:METHODES ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES LIÉS AUX MACROPHAGES[2017/12]
Entry into regional phase30.11.2016National basic fee paid 
30.11.2016Search fee paid 
30.11.2016Designation fee(s) paid 
30.11.2016Examination fee paid 
Examination procedure30.11.2016Examination requested  [2017/12]
30.11.2016Date on which the examining division has become responsible
29.06.2017Amendment by applicant (claims and/or description)
19.07.2018Application deemed to be withdrawn, date of legal effect  [2019/02]
24.08.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2019/02]
Fees paidRenewal fee
30.05.2017Renewal fee patent year 03
29.05.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO2005076819  (UNIV CALIFORNIA [US], et al) [X] 1,7,8,15 * claims 1,6-10,16-20 * * abstract * * the whole document * * example 3 * * examples 7,8 * [I] 2-6,9-14;
 [X]  - HARALD SCHEMPP ET AL, "Chlorite-Hemoprotein Interaction as Key Role for the Pharmacological Activity of the Chlorite-based Drug WF10", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH., DE, (20010101), vol. 51, no. 07, doi:10.1055/s-0031-1300079, ISSN 0004-4172, pages 554 - 562, XP055433840 [X] 1 * the whole document *

DOI:   http://dx.doi.org/10.1055/s-0031-1300079
International search[XY]WO2005076819  (UNIV CALIFORNIA [US], et al) [X] 1, 5/1, 7/1, 20-21, 33-34, 37/34, 43-44, 47 * ; paragraphs [0021], [0034]-[0035], [0051]-[0052], [0070], [0081]-[0082], [0092]-[0093], [0095], [0097]-[0098], [00124], [00131], [00133]-[00134]; claim 1 8 1 1 * [Y] 2, 3/1-2, 4/1-2, 5/2, 6, 7/6, 8/1, 8/6, 10/1, 10/6, 11/1, 11/6, 12/1, 12/6, 13, 14/1, 14/13, 15/1, 15/13, 16, 17/1, 17/16, 35-36, , 37/35-36;
 [Y]WO2011017030  (NEURALTUS PHARMACEUTICALS INC [US], et al) [Y] 11/1, 12/1, 11/6, 12/6 * ; paragraphs [0020], [00213], [00234] *;
 [Y]WO9853837  (SOUTHERN BIOSYSTEMS INC [US]) [Y] 35-35, 37/35-36 * ; page 12, lines 3 21-23 *;
 [Y]  - REALE, M. et al., "Relationship between inflammatory mediators, Abeta levels and ApoE genotype 2 in Alzheimer disease.", Current Alzheimer Research., (20120000), vol. 9, pages 447 - 457, XP 055237733 [Y] 2, 3/1-2, 4/1-2, 5/2 * ; page 450, right column, 'Plasma concentration of the inflammatory molecules ; table 2 *
 [Y]  - FORSYTH, CB et al., "Increased intestinal permeability correlates with sigmoid mucosa alpha- synuclein staining and endotoxin exposure markers in early Parkinson's disease.", PLoS ONE., (20111201), vol. 6, page e28032, XP 002677720 [Y] 6, 7/6, 8/1, 8/6, 10/1, 10/6, 11/6, 12/6 * ; table 4 *
 [Y]  - O'BRYANT, SE et al., "Decreased c-reactive protein levels in Alzheimer disease.", J Geriatr Psychiatry Neurol., (20100300), vol. 23, pages 49 - 53, XP055360633 [Y] 16, 17/16 * ; page 2, 2nd paragraph; table 1; abstract *

DOI:   http://dx.doi.org/10.1177/0891988709351832
 [Y]  - GOYAL, MK et al., "Do cytokines have any role in Wilson's disease? 2008.", Clinical & Experimental Immunology., (20080000), vol. 154, pages 74 - 79, XP055360634 [Y] 13, 14/1, 14/13, 15/1, 15/13, 17/1, 17/16 * ; page 75, right column 'The WD and 1 cytokines'; page 76, right column, 'Quantitative analysis of cytokines versus clinical and laboratory parameters' *

DOI:   http://dx.doi.org/10.1111/j.1365-2249.2008.03755.x
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.